Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 9/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CTSD | P07339 | 2/20 | 0.44 |
| ▸ | CTSE | P14091 | 2/20 | 0.44 |
| ▸ | PGC | P20142 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2937073 | 1.00 | REN (0.58) | RENSLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL2935222 | 0.90 | REN (0.69) | RENSLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL2935221 | 0.90 | REN (0.69) | RENSLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL2937657 | 0.89 | REN (0.67) | RENSLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL2937659 | 0.89 | REN (0.67) | RENSLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL2937594 | 0.86 | REN (0.79) | RENSLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL2937334 | 0.85 | REN (0.81) | RENSLC6A2SLC6A4SLC6A3CTSD | |
| SCHEMBL2937330 | 0.85 | REN (0.81) | RENSLC6A2SLC6A4SLC6A3CTSD | |
| SCHEMBL13404510 | 0.84 | REN (0.58) | RENSLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL2935462 | 0.82 | REN (0.74) | RENSLC6A2SLC6A4SLC6A3CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836163-B1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | claimed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | claimed |
| EP-1836163-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | Novartis AG (CH) | 2007-09-26 | — | — | EP | claimed |
| WO-2006066896-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | claimed |
| EP-1836163-B1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | REN, ACE, PEPD | REN 1/4885SLC6A2 472/4885SLC6A4 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.